Provided by Haymarket Medical Education
Supported by an educational grant from Seattle Genetics
Although frontline combination chemotherapy can result in durable responses, approximately one‐third of patients with HL will not have a complete response (CR) to frontline treatment, are refractory to frontline treatment, or will relapse. Of the patients who either don't experience a CR to frontline therapy or relapse, only 50% will be effectively salvaged with the standard of care for patients with relapsed or refractory HL, which is salvage chemotherapy followed by ASCT. Thus, approximately half of all of these HL patients experience disease relapse. The NCCN Guidelines recommend second‐line systemic therapy followed by response assessment with PET for all patients. Furthermore, the guidelines include everolimus and BV as options for second‐line systemic therapy for patients with relapsed or refractory CHL and bendamustine and lenalidomide for third‐line therapy.
Disclosure of Conflicts of Interest Statement
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Disclosures are as follows: Stephen M. Ansell, MD, PhD:
Bristol-Myers Squibb, Seattle Genetics (research funding for clinical trials)
The staff, planners, and managers at Haymarket Medical Education have no relevant financial relationships to disclose.
The reviewers at CME Peer Review have no relevant financial relationships to disclose. Accreditation/Designation of Credit Statement
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit
™. Physicians should claim only those credits commensurate with the extent of their participation in the activity. Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Seattle Genetics and HME do not recommend the use of any agent outside of the labeled indications. Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Seattle Genetics and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Method of Participation
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time. Contact Information
If you have any questions relating to the accreditation of this activity, please contact Julie A. Tagliareni at email@example.com
COURSE VIEWING REQUIREMENTS
Leukemia and Lymphoma Learning Center
|Supported Browsers: |
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above